The potential of GLP-1 RAs to effectively reduce blood glucose with minimal risk of hypoglycemia and simultaneously promote weight loss has been a breakthrough in the modern diabetes management; however, their revolutionary impact on clinical practice is based on data showing that they can alleviate cardiorenal risk by exerting anti-inflammatory and anti-atherosclerotic effects on the heart, vessels, and kidneys, improve the lipid profile and mitigate oxidative damage and endothelial dysfunction [14,15,16]. This evidence concerns the gene GCG and diabetes mellitus.